Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: Results from the PSUNRISE trial

Journal of Drugs in Dermatology

Volumn 12, Issue 8, 2013, Pages 874-880

  Kalb, Robert E ^a   Blauvelt, Andrew ^b   Sofen, Howard L ^c   Chevrier, Marc ^d   Amato, David ^d   Calabro, Stephen ^d   Wang, Jim ^e   Schenkel, Brad ^f   Gottlieb, Alice B ^g  

^a UNIVERSITY AT BUFFALO   (United States)

^b OREGON MEDICAL RESEARCH CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Janssen Biotech Inc   (United States)

^e JOHNSON AND JOHNSON   (United States)

^f Janssen Scientific Affairs LLC   (United States)

^g TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; INFLIXIMAB;

ADULT; AGED; ARTICLE; BODY REGIONS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; MALE; MULTICENTER STUDY; PROSPECTIVE STUDY; PSORIASIS; QUALITY OF LIFE; QUALITY OF LIFE INDEX; SCORING SYSTEM; SHORT FORM 36; STUDENT T TEST; TREATMENT RESPONSE; VISUAL ANALOG SCALE;

ADULT; ANTIBODIES, MONOCLONAL; DERMATOLOGIC AGENTS; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSORIASIS; QUALITY OF LIFE; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84882300951     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Kimball AB, Jacobson C, Weiss S, et al. The psychosocial burden of psoriasis. Am J Clin Dermatol. 2005; 6: 383-392.
2. Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999; 41: 401-407.
3. Fortune DG, Main CJ, O'Sullivan TM, Griffiths CEM. Quality of life in patients with psoriasis: the contribution of clinical variables and psoriasis-specific stress. Br J Dermatol. 1997; 137: 755-760.
4. Hong J, Koo B, Koo J. The psychosocial and occupational impact of chronic skin disease. Dermatol Ther. 2008; 21: 54-59.
5. Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol. 2010; 146: 891-895.
6. th annual meeting of the American Academy of Dermatology, San Diego, California, March 16-20, 2012.
7. Hermanns-Le T, Berardesca E, Pierard GE, et al. Challenging regional psoriasis and ustekinumab biotherapy: impact of the patterns of disease. J Biomed Biotech. 2012:413767, 2012.
8. Kragballe K. Management of difficult to treat locations of psoriasis: scalp, face, flexures, palm/soles and nails. Curr Prob Dermatol. 2009;38:160-171.
9. Crowley J. Scalp psoriasis: an overview of the disease and available therapies. J Drugs Dermatol. 2010; 9: 912-918.
10. Pettey AA, Balkrishnan R, Rapp SR, et al. Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: implications for clinical practice. J Am Acad Dermatol. 2003; 49: 271-275.
11. De Jong EM, Seegers BA, Gulinck MK, et al. Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1,728 patients. Dermatology. 1996; 193: 300-303.
12. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005; 366: 1367-1374.
13. Menter A, Feldman SR, Weinstein GD, et al. A randomized, comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007;50:31.e1-15.
14. Leonardi CL, Powers JL, Matheson RT, et al., for the Etanercept Psoriasis Study Group. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349:2014-2022.
15. Reich K, Nestle FO, Papp K, et al. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial. Br J Dermatol. 2006;154:1161-1168.
16. Feldman SR, Gottlieb AB, Bala M, et al. Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis. Br J Dermatol. 2008; 159: 704-710.
17. Vender R, Lynde C, Gilbert M, et al. Etanercept improves quality of life outcomes and treatment satisfaction in patients with moderate to severe plaque psoriasis in clinical practice. J Cutan Med Surg. 2012; 16: 407-416.
18. Gottlieb AB, Kalb RE, Blauvelt A, et al. The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: Results of a prospective, multicenter, open-label study. J Am Acad Dermatol. 2012; 67: 642-650.
19. Fredriksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica. 1978; 157: 238-244.
20. Finlay AY, Khan GK. Dermatology life quality index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994; 19: 210-216.
21. Basra MKA, Fenech R, Gatt RM, et al. The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results. Br J Dermatol. 2008; 159: 997-1035.
22. Hongbo Y, Thomas CL, Harrison MA, et al. Translating the science of quality of life into practice: What do Dermatology Life Quality Index scores mean? J Invest Dermatol. 2005; 125: 659-664.
23. Finlay AY, Khan GK. Dermatology Life Quality Index: information & conditions concerning use. http://www.dermatology.org.uk/quality/dlqi/quality- dlqi-info.html. Published December 6, 1993. Accessed May 6, 2013.
24. Euro Qol Group. EQ-5D. An instrument to describe and value health. Available at: http://www.euroqol.org. Accessed May 6, 2013.
25. The Euro QoL Group. Euro Qol - a new facility for the measurement of health-related quality of life. Health Policy. 1990; 16: 199-206.
26. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992; 30: 473-483.
27. Katugampola RP, Lewis VJ, Finlay AY. The Dermatology Life Quality Index: assessing the efficacy of biological therapies for psoriasis. Br J Dermatol. 2007; 156: 945-950.
28. Dolan P. Modeling variations for Euro QOL health status. Med Care. 1997; 35: 1095-1108.
29. Shikiar R, Willian MK, Okun MM, et al. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. Health Qual Life Outcomes. 2006; 4: 1-12.
30. Samsa G, Edelman D, Rothman ML, et al. Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II. Pharmacoeconomics. 1999; 15: 141-155.
31. Lebwohl M, Papp K, Han C, et al. Ustekinumab improves health-related quality of life in patients with moderate-to-sevre psoriasis: results from the PHOENIX 1 trial. Br J Dermatol. 2010;162:137-146.
32. Shikiar R, Heffernan M, Langley RG, et al. Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patientreported outcomes from a Phase II randomized controlled trial. J Dermatol Treat. 2007; 18: 25-31.